Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.64 |
| ▸ | ABCB1 | P08183 | 11/20 | 0.54 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2019909 | 1.00 | KCNH2 (0.64) | KCNH2ABCB1HTR7LMNAGAA | |
| SCHEMBL2021781 | 1.00 | KCNH2 (0.64) | KCNH2ABCB1HTR7LMNAGAA | |
| SCHEMBL2021136 | 0.91 | KCNH2 (0.64) | KCNH2ABCB1HTR7LMNAGAA | |
| SCHEMBL2021138 | 0.91 | KCNH2 (0.64) | KCNH2ABCB1HTR7LMNAGAA | |
| SCHEMBL2024412 | 0.91 | KCNH2 (0.64) | KCNH2ABCB1HTR7LMNAGAA | |
| SCHEMBL2023751 | 0.87 | KCNH2 (0.61) | KCNH2ABCB1HTR7LMNAGAA | |
| SCHEMBL2020693 | 0.87 | KCNH2 (0.61) | KCNH2ABCB1HTR7LMNAGAA | |
| SCHEMBL2020697 | 0.87 | KCNH2 (0.61) | KCNH2ABCB1HTR7LMNAGAA | |
| SCHEMBL2022600 | 0.85 | KCNH2 (0.82) | KCNH2HTR7LMNAL3MBTL1 | |
| SCHEMBL4252519 | 0.85 | KCNH2 (0.82) | KCNH2HTR7LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079852-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | LIOTTA DENNIS C (US) | 2014-01-30 | — | — | US | disclosed |
| US-8420680-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110160223-A1 | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders | EMORY UNIVERSITY | 2011-06-30 | — | — | US | disclosed |
| US-20110160223-A1 | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders | EMORY UNIVERSITY | 2011-06-30 | — | — | US | disclosed |
| WO-2009137843-A2 | NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | EMORY UNIVERSITY (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | EMORY UNIVERSITY | 2009-10-08 | — | — | US | disclosed |
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | EMORY UNIVERSITY | 2009-10-08 | — | — | US | disclosed |
| WO-2009006437-A1 | NMDA RECEPTOR ANTAGONISTS FOR NEUROPROTECTION | EMORY UNIVERSITY (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | KCNH2 137/4885ABCB1 2227/4885HTR7 443/4885 |
| US-20110160223-A1 | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders | GRIN2A, GRIN2B, GRIN1 | KCNH2 469/4885ABCB1 2367/4885HTR7 111/4885 |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | KCNH2 135/4885ABCB1 2170/4885HTR7 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.